A clinical briefing on Byooviz availability, prescribing considerations, and tools to help your patients access anti-VEGF treatment in 2026.
If your practice prescribes or administers anti-VEGF injections, you've likely encountered questions — from patients, staff, and colleagues — about the availability of Byooviz (Ranibizumab-nuna). While Byooviz is not currently on the FDA's official drug shortage list, real-world access challenges persist, and they directly affect your patients' treatment continuity.
This article provides an evidence-based overview of the current Byooviz landscape, including availability, prescribing considerations, cost and reimbursement factors, and resources to help your practice and patients navigate the situation.
Understanding where Byooviz fits in the anti-VEGF market requires context:
Byooviz is FDA-approved for three indications at the 0.5 mg dose:
Notably, Byooviz is not approved for diabetic macular edema (DME) or diabetic retinopathy (DR) — indications for which Lucentis is approved at the 0.3 mg dose. Byooviz's single-dose vial only delivers the 0.5 mg dose. This is a critical consideration for practices with a significant diabetic patient population.
Since October 2023, Byooviz carries an interchangeability designation, allowing pharmacies and providers to substitute it for Lucentis without additional prescriber approval in most states. For practices using buy-and-bill, this means stocking decisions can be made at the practice level based on cost and availability.
Byooviz is administered as a 0.5 mg (0.05 mL) intravitreal injection approximately once monthly (every 28 days). Standard aseptic intravitreal injection technique applies. The medication must be refrigerated (2°C to 8°C) and protected from light.
For detailed prescribing information, consult the full Byooviz prescribing overview.
The current availability of Byooviz is best described as variable by practice and region. Contributing factors include:
Anti-VEGF injections operate under the buy-and-bill model, where the provider purchases the drug and seeks reimbursement from the payer. Reimbursement is typically based on average sales price (ASP) + 6% under Medicare Part B. For biosimilars, the reimbursement calculation can be less favorable than for established products with higher ASPs, potentially reducing the financial incentive to stock Byooviz.
Lucentis market share has declined substantially as Eylea, Vabysmo, and off-label Avastin dominate the anti-VEGF market. With Lucentis holding approximately 9% market share, the addressable market for Ranibizumab biosimilars is limited. Some practices have determined that stocking Ranibizumab products — including Byooviz — is not warranted given their patient mix.
Byooviz is distributed through specialty channels, not traditional wholesale networks. Practices must maintain relationships with specialty distributors, and any disruption in these channels can create localized access issues.
Providers should be aware of the following cost dynamics:
Medicare Part B reimburses biosimilars at the biosimilar's ASP + 6% of the reference product's ASP. For qualified biosimilars, this may offer a slight margin advantage, but practices should verify current ASP-based reimbursement rates with their billing team.
For commercially insured patients, the Biogen Copay Program can reduce out-of-pocket costs to as low as $0. Enrollment is available through Biogen Biosimilar Support Services at 1-877-422-8360.
For uninsured or underinsured patients, Biogen's patient assistance program may provide Byooviz at no cost. Additional resources include NeedyMeds.org and RxAssist.org.
For more detailed cost information, see our provider's guide to saving patients money on Byooviz.
Medfinder offers a provider-facing tool to help your patients locate specialty medications when your practice can't supply them. Rather than sending patients away empty-handed, you can direct them to Medfinder to find another provider with Byooviz in stock.
Biogen's dedicated support team (1-877-422-8360) can assist with:
When Byooviz is unavailable, consider these therapeutic alternatives:
For clinical comparison details, see our article on alternatives to Byooviz.
Several developments may impact Byooviz availability and the broader anti-VEGF market in the coming years:
Staying informed about these developments will help your practice make proactive formulary and stocking decisions.
Byooviz remains a clinically effective and cost-efficient option for appropriate patients, but real-world availability challenges require proactive management. Understanding the market dynamics, maintaining relationships with specialty distributors, and leveraging tools like Medfinder and Biogen Support Services can help ensure your patients maintain uninterrupted anti-VEGF therapy.
The bottom line: treatment gaps pose a greater risk to patient outcomes than switching between anti-VEGF agents. When Byooviz isn't available, have a documented protocol for therapeutic substitution to keep patients on track.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
